drugset

drugset / Trial / NCT02508506

Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function

NCT02508506 ↗

Phase 1 Completed 22 enrolled Alkermes, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the effect of various degrees of renal function on the pharmacokinetics and safety of ALKS 5461.

Timeline

Start: 2015-07
Primary completion: 2015-12
Completion: 2015-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ALKS 5461	Unknown	—	Oral

Indications